The Los Angeles Post
U.S. World Business Lifestyle
Today: March 16, 2025
Today: March 16, 2025
Maggie Fick

Maggie Fick

Staff Writer

Latest From Maggie Fick

Europe|Food|Health|Science

How a Novo Nordisk Foundation-funded project sparked ultra-processed food fight

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the world understands ultra-

Business|Europe|Finance|Health|Stock Markets

Roche secures Zealand obesity drug candidate for up to $5.3 billion

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker

Roche secures Zealand obesity drug candidate for up to $5.3 billion
Africa|Europe|MidEast|Political|US|World

US global disaster response teams unable to deploy following USAID shutdown, sources say

A world-renowned U.S. program for international disaster and crisis assistance can no longer deploy in the event of a major emergency due to the Trump administration's

US global disaster response teams unable to deploy following USAID shutdown, sources say
Business|Economy|Europe|Health

Novo Nordisk defends next-gen obesity drug CagriSema, details new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in

Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
Business|Economy|Europe|Health

Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with

Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
Business|Europe|Health

Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a

Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
Africa|Health|Political|US|World

Despite waiver from U.S. on aid freeze, health and humanitarian groups uncertain if they can proceed

Health and humanitarian groups around the world were still uncertain on Wednesday if and how they could resume work after

Despite waiver from U.S. on aid freeze, health and humanitarian groups uncertain if they can proceed
Africa|Health|Political|US|World

Trump's order will stop aid group feeding malnourished children in Ethiopia, sources say

The Trump administration's freeze on U.S. foreign aid globally has included a stop-work order to a program run by aid group Action Against Hunger helping severely

Trump's order will stop aid group feeding malnourished children in Ethiopia, sources say
Asia|Economy|Health|Political|World

Trump's freeze on US aid rings alarm bells from Thailand to Ukraine

Field hospitals in Thai refugee camps, landmine clearance in war zones, and drugs to treat millions suffering from

Trump's freeze on US aid rings alarm bells from Thailand to Ukraine
Uncategorized

Exclusive-Catalent nears settlement with Elliott for board seats -sources

Catalent Inc is close to reaching a settlement with Elliott Investment Management that would lead to a shake-up of the U.S. contract drug manufacturer’s board of directors after its share price lost half of its value in the last year. The company is poised to agree to add four new directors proposed by Elliott to its board, which currently has 12 members, people familiar with the situation said on Monday. The sources declined to be identified because the information is confidential and cautioned a deal could still collapse at the last minute. Spokespeople

Exclusive-Catalent nears settlement with Elliott for board seats -sources
Business|Economy|Finance|Health

Weight-loss drugs fuel boom for firms that fill syringes

Contract drug manufacturers seeking to tap into the booming market for weight-loss drugs are investing billions of dollars to expand or build factories that fill the

Weight-loss drugs fuel boom for firms that fill syringes
Business|Economy|Health|US

Novo Nordisk to 'significantly' boost U.S. Wegovy doses next year

Novo Nordisk said on Thursday it will supply "significantly" more doses of Wegovy in the U.S. next year, even as it cautioned

Novo Nordisk to 'significantly' boost U.S. Wegovy doses next year
Business|Economy|Health

Novo Nordisk, Lilly see insatiable demand for weight-loss drugs

Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their

Novo Nordisk, Lilly see insatiable demand for weight-loss drugs
Health|Lifestyle|Technology

How well-off Brits still buy Ozempic online for weight loss

John, a tech executive who has been battling weight gain since his 30s, has a nine-month supply in his refrigerator.

How well-off Brits still buy Ozempic online for weight loss
Business|Health|Science|Technology|US

Wegovy maker Novo Nordisk signs research partnerships with U.S. biotech firms

Blockbuster weight-loss drug maker Novo Nordisk announced on Thursday research collaborations with two U.S. biotech firms, part of its efforts to stay ahead in big

Wegovy maker Novo Nordisk signs research partnerships with U.S. biotech firms
Business|Health|US

Exclusive-US FDA finds new manufacturing lapses at Eli Lilly plant

U.S. inspectors recently uncovered new manufacturing problems at an Eli Lilly plant that has been under scrutiny by federal investigators,

Exclusive-US FDA finds new manufacturing lapses at Eli Lilly plant
Business|Economy|Europe|Health

As Lilly competition heats up, Novo CEO details strategy for new Wegovy launches

Novo Nordisk will target launches of its mega popular obesity shot Wegovy in markets where it already has strong sales of its

As Lilly competition heats up, Novo CEO details strategy for new Wegovy launches
Health|Science

Novo kidney trial finds Ozempic cuts cardiac risks in diabetics

Novo Nordisk's widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, a large late-stage study

Novo kidney trial finds Ozempic cuts cardiac risks in diabetics
Business|Europe|Health

Novo Nordisk hopes to launch experimental obesity drug this decade

Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the

Novo Nordisk hopes to launch experimental obesity drug this decade
Business|Finance|Stock Markets

AstraZeneca leaps after smashing first-quarter forecasts

AstraZeneca sailed past market expectations for quarterly revenue and profit on Thursday, boosted by demand for its blockbuster drugs and steady sales from

AstraZeneca leaps after smashing first-quarter forecasts
Business|Economy|Finance|Health|Science

GSK raises profit outlook on strong vaccine, HIV drug sales

GSK raised its full-year profit forecast on Wednesday on strong demand for its common respiratory vaccine and specialty HIV medicines, though it expects sales

GSK raises profit outlook on strong vaccine, HIV drug sales
Business|Europe|Health

Novo Nordisk trims price for blockbuster obesity drug as competition heats up

Novo Nordisk raised its 2024 outlook on Thursday as the Danish drugmaker races to boost output of its Wegovy weight-loss treatment, while

Novo Nordisk trims price for blockbuster obesity drug as competition heats up
Health|MidEast|World

Main maternity hospital in Rafah stops admitting patients

The main maternity hospital in the Gaza Strip's crowded southern city of Rafah has stopped admitting patients, the United Nations Population Fund (UNFPA) said on

Main maternity hospital in Rafah stops admitting patients
Business|Finance|Stock Markets

AstraZeneca aims for $80 billion in total revenue by 2030

AstraZeneca aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday, boosted by the expected launch of 20 new medicines and through

AstraZeneca aims for $80 billion in total revenue by 2030
Health|Science

Wegovy users have less kidney-related health problems, analysis of Novo study finds

Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large study, according to a new analysis the

Wegovy users have less kidney-related health problems, analysis of Novo study finds

Follow